F-351 Market Size, Forecast, and Emerging Insight - 2032
상품코드:1462293
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
약제 요약
하이드로니돈(F-351)은 GNI의 전액 출자회사인 상하이 지노믹스(Shanghai Genomics)가 개발한 비스테로이드성 항염증제(NSAID)입니다. 하이드로니돈은 간 성상세포의 증식을 억제하고 TGF-B 신호전달 경로를 억제하며, 상하이 지노믹스는 F-351을 만성 간염(HBV)으로 인한 간섬유증 치료제로 개발하고 있습니다. 추가 적응증으로 F-351은 비알코올성 지방간염(NASH) 간질환, 비알코올성 지방간질환(NAFLD), 만성신부전 치료제로 개발될 가능성이 있습니다.
현재 만성 B형 간염 간섬유증에 대한 하이드로니돈의 유효성과 안전성을 확인하기 위해 3상 임상(NCT05115942)을 진행 중입니다. 이 임상시험은 2024년 6월까지 완료될 예정입니다.
중국의 B형 만성 간염용 F-351에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 B형 만성 간염에서의 F-351 개요
제품의 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 신치료법)
제5장 F-351 시장 평가
B형 만성 간염에서 F-351의 시장 전망
중국 분석
중국의 B형 만성 간염용 F-351의 시장 규모
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
영문 목차
영문목차
"F-351 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about F-351 for chronic hepatitis B in China. A detailed picture of the F-351 for chronic hepatitis B in China for the study period 2019 -2032 is provided in this report along with a detailed description of the F-351 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the F-351 market forecast analysis for chronic hepatitis B in China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.
Drug Summary:
Hydronidone (F-351) is a nonsteroidal anti-inflammatory drug (NSAID) developed by Shanghai Genomics, a wholly owned subsidiary of GNI. It inhibits hepatic stellate cell proliferation and also the TGF-B signaling pathway. Shanghai Genomics is developing F-351 to treat liver fibrosis induced by chronic hepatitis (HBV). For additional indications, F-351 has the potential to be further developed for Non-alcoholic steatohepatitis (NASH) liver disease, Non-alcoholic fatty liver disease (NAFLD), and chronic kidney failure.
Currently, the drug is being evaluated in a Phase III (NCT05115942) trial to confirm the efficacy and safety of hydronidone in treating chronic hepatitis B liver fibrosis. The trial is anticipated to be complete by June 2024.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the F-351 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
Elaborated details on F-351 regulatory milestones and other development activities have been provided in this report.
The report also highlights the F-351 research and development activities in chronic hepatitis B across China.
The report also covers the patents information with expiry timeline around F-351.
The report contains forecasted sales of F-351 for chronic hepatitis B till 2032.
Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
The report also features the SWOT analysis with analyst views for F-351 in chronic hepatitis B.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
F-351 Analytical Perspective by DelveInsight
In-depth F-351 Market Assessment
This report provides a detailed market assessment of F-351 for chronic hepatitis B in China. This segment of the report provides forecasted sales data from 2024 to 2032.
F-351 Clinical Assessment
The report provides the clinical trials information of F-351 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence F-351 dominance.
Other emerging products for chronic hepatitis B are expected to give tough market competition to F-351 and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of F-351 in chronic hepatitis B.
Our in-depth analysis of the forecasted sales data of F-351 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the F-351 in chronic hepatitis B.
Key Questions:
What is the product type, route of administration and mechanism of action of F-351?
What is the clinical trial status of the study related to F-351 in chronic hepatitis B and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the F-351 development?
What are the key designations that have been granted to F-351 for chronic hepatitis B?
What is the forecasted market scenario of F-351 for chronic hepatitis B?
What are the forecasted sales of F-351 in China?
What are the other emerging products available and how are these giving competition to F-351 for chronic hepatitis B?
Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?
